Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alferon LDO in SARS-exposed or normal volunteers
NCT00215826Phase 2Completed
- Sponsor
- AIM ImmunoTech
- Start
- Nov 2004
- Primary completion
- Apr 2006
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of interferon alfa-n3 in severe acute respiratory syndrome (SARS), sponsored by AIM ImmunoTech. Started Nov 2004; status: completed.
02
Drugs
interferon alfa-n3
03
Conditions
severe acute respiratory syndrome (SARS)
Beyond the preview
Go deeper on NCT00215826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215826.